SCYNEXIS (SCYX)
Develops antifungal and rare-disease drug candidates under a GSK licensing model.
$5.30
At close+0.13 (+2.51%)
Something off on this page? Send us feedback.
Next report
Nov 4, 2026
in 62 days
EPS estimate
−$0.72
Revenue estimate
$147.0K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.17−$0.14−$0.14−$0.17$0.25−$3.36$0.63Pending
Estimate−$0.23−$0.23−$0.23−$0.21$0.29−$0.80−$0.51−$0.72
Surprise+26.1%+39.1%+39.1%+19.0%−13.8%−320.0%+224.3%—
RevenueReportedEstimate
May '25Aug '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$257.0K$1.4M$1.4M$334.0K$18.6M—$235.0KPending
Estimate$137.0K$154.0K$154.0K$133.3K$8.1M$77.0K$80.3K$147.0K
Surprise+87.6%+785.7%+785.7%+150.5%+130.2%—+192.5%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.72 | — | — |
| Aug 2026 | −$0.51 | $0.63 | +224.3% |
| May 2026 | −$0.80 | −$3.36 | −320.0% |
| Mar 2026 | $0.29 | $0.25 | −13.8% |
| Nov 2025 | −$0.21 | −$0.17 | +19.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | −$0.72 | — | — | $147.0K | — | — | — |
| Aug 10, 2026 | −$0.51 | $0.63 | +224.3% | $80.3K | $235.0K | +192.5% | −6.2% |
| May 11, 2026 | −$0.80 | −$3.36 | −320.0% | $77.0K | — | — | −5.3% |
| Mar 4, 2026 | $0.29 | $0.25 | −13.8% | $8.1M | $18.6M | +130.2% | +2.3% |
| Nov 5, 2025 | −$0.21 | −$0.17 | +19.0% | $133.3K | $334.0K | +150.5% | −5.5% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 14, 2025 | |||||||
| Aug 13, 2025 | |||||||
| May 16, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 12, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 8, 2024 | |||||||
| Mar 29, 2024 | |||||||
| Mar 28, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 15, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 29, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 16, 2021 | |||||||
| May 17, 2021 | |||||||
| Mar 29, 2021 | |||||||
| Nov 6, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 11, 2020 | |||||||
| Mar 11, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 8, 2019 | |||||||
| Mar 14, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 8, 2018 | |||||||
| Mar 13, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 8, 2017 | |||||||
| Mar 13, 2017 | |||||||
| Nov 7, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 9, 2016 | |||||||